GlassScriptPhysician profile
Alexander Bangiev
NPI 1689636375
$2,987.13
in general payments reported to CMS, 2019-2025
24 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $166 · 2021: $351 · 2022: $438 · 2023: $399 · 2024: $1,034 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $775.84 | 2021-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $472.29 | 2020-2025 | Lokelma, Farxiga |
| Ardelyx, INC. | $257.28 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Amarin Pharma, INC. | $238.51 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $237.33 | 2024-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $161.09 | 2025 | Esprit |
| Novo Nordisk INC | $148.87 | 2021-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $114.56 | 2022-2025 | |
| Amgen INC. | $80.73 | 2020-2024 | Prolia, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.41 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $50.18 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $48.92 | 2024-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $48.41 | 2022 | |
| Harmony Biosciences LLC | $46.53 | 2025 | |
| Mallinckrodt Hospital Products INC. | $35.81 | 2025 | Acthar |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.82 | 2020-2021 | |
| Fresenius USA Manufacturing, INC. | $30.87 | 2025 | |
| Ironwood Pharmaceuticals, INC | $25.00 | 2024 | |
| Optinose US, INC. | $20.84 | 2024 | |
| Paratek Pharmaceuticals, INC. | $20.06 | 2024 | Nuzyra |
| Phadia US INC. | $20.04 | 2022 | |
| Insmed, INC. | $18.04 | 2023 | Arikayce |
| Abbvie INC. | $18.03 | 2021 | |
| Vifor Pharma, INC. | $17.67 | 2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Bangiev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.